These are some of the early bird analyst upgrades and positive calls we are seeing this Thursday morning with more than two hours to the open:
Jon C. Ogg
September 11, 2008
Out of the daily movers this last week, many of the top winners and losers were from news in many of the smaller biotech stocks. We prepared a list of the winners and sinners from our daily review at BioHealthInvestor.com and gave a summary regarding the moves on each. It is becoming more obvious that many small and mid-sized biotechs are going to be gobbled up by European or Asian biotech and pharma companies seeking the dollar-discount right now.
For starters, we ran a summary of the key moving pieces out of the American Society of Clinical Oncology (ASCO). No review would be complete without it. Stocks covered: (AVAN, PFE, CELG, IMCL, DNA)
ACQUISITION NEWS
Tercica, Inc. (NASDAQ: TRCA) bites the dust as its own company the latest small cap biotech received a huge premium acquisition from a foreign buyer, with a 104% premium. FULL DETAILS
MAJOR WINNERS
Acorda Therapeutics Inc. (NASDAQ: ACOR) had a great week after it announced positive data from a second Phase III study of its Fampridine-SR for patients’ walking abilities in MS patients. FULL DETAILS
Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) surged after reaching its primary endpoint in Phase III trial of Denufosol for Cystic Fibrosis. FULL DETAILS
Oncolytics Biotech Inc. (NASDAQ: ONCY) gained after the Canadian biotech’s positive Phase II studies of intravenous REOLYSIN® in patients with sarcomas metastatic to the lung. FULL DETAILS
Pharmacyclics Inc. (NASDAQ: PCYC) gained after its Phase 1/2 trial of motexafin gadolinium plus antibody targeted radiation therapy showed a high complete response rate in patients with non-Hodgkin’s lymphoma. FULL DETAILS
Sequenom Inc. (NASDAQ: SQNM) surged after it announced its progress with a non-invasive technology that detects Down syndrome. FULL DETAILS
MAJOR LOSERS
Indevus Pharmaceuticals Inc. (NASDAQ: IDEV) tanked after an FDA request should cause a two-year delay in approving NEBIDO. FULL DETAILS
MIXED REVIEW
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is one we gave a full pro and con review covering the upside of the stock and the negative side of the stock. FULL DETAILS
Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) was a strange stock this week. The company reported great news but shares slid before the market figured out it had misinterpreted news in the company. INITIAL DETAILS
Jon C. Ogg
June 7, 2008
This week we got to see critical SEC filings showing holdings of many key and influential investors. Included in these filings were billionaire George Soros, a billionaire whom is loved by some and much less ‘well thought of’ by others over his currency trading history of over his MoveOn.org attempts. Either way, investors still watch Soros. These are the holdings of Soros Fund Management LLC as of December 31, 2007. These were listed as the top holdings and are not at all his entire positions. Soros Fund Management LLC was listed as having some $2.269 Billion in the total filing, and these positions here only equate to $360+ million, so there are many more positions. As with all of these holdings, these positions may have changed or been eliminated as of the dates noted. Here is a summary of his larger positions with a dollar amount provided by Soros as filer and a share count:
As Soros himself says …."Contrary to the tenets of market fundamentalism, financial markets do not tend towards equilibrium; they are crisis prone."
Other billionaires and their holdings filed this week:
Bill Gates
Carl Icahn
Warren Buffett
Jon C. Ogg
February 16, 2008